Clinical profile and risk factors for mortality among COVID-19 inpatients at a tertiary care centre in Bengaluru, India

Marimuthu, Yamini; Kunnavil, Radhika; Anil, N S; Nagaraja, Sharath Burugina; Satyanarayana, N.; Kumar, Jeetendra; Ramya, B.

doi:10.4081/monaldi.2021.1724

Cited by 10 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, we included 34 studies which included 23,034 patients totally, of which 14,786 patients were male and 8,208 were females. [ 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 ] One study did not mention distribution of the sample size between male and female. All the 34 studies were based on Indian population and were performed at different hospitals in India.…”

Section: Resultsmentioning

confidence: 99%

Prevalence of co-morbidities and its association with mortality in Indian patients with COVID-19: A meta-analysis

Jindal¹,

Gupta²,

Khan³

et al. 2022

Indian J Anaesth

View full text Add to dashboard Cite

Background and Aims: Coronavirus disease 2019 (COVID 19) has spread to every corner of the world and has led to significant health consequences, especially in patients with co morbidities. This study aimed to estimate the prevalence of co morbidities among COVID 19 patients in the Indian population and their association with mortality. Methods: PubMed, Google Scholar, and World Health Organization website were searched for Indian studies on COVID 19 published from February 2020 up to 20 May 2021. English language publications from India, studies reporting epidemiological characteristics, prevalence of co morbidities and in hospital mortality were included in the meta analysis. Results: 34 studies were identified with a total of 23,034 patients. The pooled prevalence for co morbidities in COVID 19 patients was 18.1% [95% confidence interval (CI), 13.3 to 24.3%] for hypertension, 17.7% (95% CI, 12.2 to 25.1%) for diabetes, 7.9% (95% CI, 4.6 to 13.4%) for hypothyroidism and 7.7%(95% CI, 4.8 to 12. 1%) for cardiovascular diseases. For chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), cerebrovascular diseases, asthma, chronic liver disease, tuberculosis and cancer, the pooled prevalence was less than 4%. Additionally, the mortality risk was increased significantly in patients with CKD [odds ratio (OR) = 4.1], COPD (OR = 3.9), diabetes (OR = 3.7), cardiovascular diseases (OR = 4.07), tuberculosis (OR = 6.11), chronic liver disease (OR = 8.5), malignancy (OR = 1.89) and hypertension (OR = 2.9). Cerebrovascular diseases, hypothyroidism and asthma were not associated with increased mortality. Conclusion: Co-morbidities are more prevalent in COVID 19 hospitalised patients and the presence of co morbidities is associated with increased risk of mortality in Indian COVID 19 patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence of co-morbidities and its association with mortality in Indian patients with COVID-19: A meta-analysis

Jindal¹,

Gupta²,

Khan³

et al. 2022

Indian J Anaesth

View full text Add to dashboard Cite

show abstract

“…In our study, the majority of the deaths (53%) occurred in the older age group of more than 60 years, which was similar to findings by Priya S et al . [ 7 ] in which 59% of deaths occurred in the older age group and various studies[ 5 24 25 26 27 28 ] across the globe. Age-related factors such as declining immune functions, variations in quality and quantity of mucins and glycoproteins on the mucosal barriers and a gradual decline in clearing the inhaled particles could be attributed to increased risk of mortality among the elderly population.…”

Section: Discussionmentioning

confidence: 99%

“…Studies by Marimuthu Y et al . [ 5 ] reported that 1.4 (95% CI, 0.6–3.0) times in 41–50 years of age group, male gender [OR 1.7 (95% CI, 1.1–2.6)], smoking [OR 6.2 (95% CI, 3.6–10.8)] and co-morbidities [OR 4.0 (95% CI, 2.5–6.3)] were significantly associated with increased mortality among COVID-19 patients. The study conducted in a rural part of India by Priya S[ 7 ] reported the same, indicating that the presence of these multiple risk factors will increase the mortality among the COVID-19 patients.…”

Section: Discussionmentioning

confidence: 99%

“…In India, situation is even different among the states with regard to the presentation of COVID-19. [ 5 6 7 ] One-third of the COVID-19 infections usually are asymptomatic and recover without any complications. [ 8 ] The majority of the mild or moderate cases present with features like fever, cough, breathlessness, myalgia, fatigue, pneumonia and anosmia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicoepidemiological profile of COVID-19 patients admitted at a teaching institute in a hilly area of India during the second wave—A retrospective observational study

Udayar

Marella

Naidu

et al. 2022

J Family Med Prim Care

View full text Add to dashboard Cite

Introduction: COVID-19 ongoing pandemic has resulted in millions of deaths globally, and India has recorded the second highest number of confirmed cases till now. In the absence of effective treatment, it becomes crucial to know about the course of the disease in hospital settings for effective patient care. The present study discusses the clinicoepidemiological, haematological and biochemical determinants among survivors and non-survivors of COVID-19 patients admitted to a tertiary care hospital in a hilly area. Methods: A record-based cross-sectional study was carried out at the government hospital from March 2021 to June 2021, which included all confirmed cases of 18 years and above. Demographic details, delayed admission, co-morbidities and laboratory parameters were collected. Results: Out of a total of 1267 COVID-19 patients, the mean age of survived and succumbed was 50.77 ± 16.1 and 60.50 ± 14.2 years, respectively ( P < 0.001). The mean survival time in males (17.7 days) was lesser compared to that in females (20.3 days). Two hundred and twelve of them practised self-medication. The mean duration of delayed testing (2.95 ± 2.3 vs 3.36 ± 2.2 days), mean values of haemoglobin (11.39 ± 2.1 vs 12.5 ± 1.7), platelet count (193.8 ± 94.6 vs 253.1 ± 105.9), leucocyte count (11.53 ± 5.72 vs 9.11 ± 5.21), neutrophil–lymphocyte ratio (10.0 ± 2.9 vs 7.3 ± 3.5), urea (61.16 ± 51.8 vs 30.2 ± 21.2) and creatinine (2.13 ± 2.9 vs. 1.1 ± 0.3) among the two groups were statistically significant ( P < 0.001). Increasing age, contact history, hypertension [OR 3.2 (95% CI, 1.40–7.39)], diabetes [OR 1.9 (95% CI, 0.81–4.40)] and chronic kidney disease [OR 15.4 (95% CI, 5.23–45.71)] were found to be associated with increased risk of mortality ( P < 0.005). Conclusions: Public health interventions like contact tracing, testing and early identification of laboratory parameters and treatment on priority would help in providing effective care so that the mortality can be reduced.

show abstract

“…A total of 114 eligible studies 2 , 3 , 4 , 5 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 ,…”

Section: Tableunclassified

Prevalence of comorbid tuberculosis amongst COVID‐19 patients: A rapid review and meta‐analysis

Wang

et al. 2021

Int J Clin Pract

View full text Add to dashboard Cite

Tuberculosis is reported to be associated with the severity and mortality amongst patients with coronavirus disease 2019 (COVID-19). 1 However, the reported prevalence of comorbid tuberculosis amongst COVID-19 patients varied greatly across the published studies. For example, the low prevalence of comorbid tuberculosis amongst COVID-19 patients was reported in Tian et al's study (0.4%) 2 and Yan et al's study (0.2%) 3 and the relatively high prevalence of comorbid tuberculosis amongst COVID-19 patients was reported in Hu et al's study (4.5%) 4 and Zhang et al's study (9.0%). 5 Therefore, it is needed to quantitatively estimate the pooled prevalence of comorbid tuberculosis amongst COVID-19 patients using a meta-analysis.

show abstract

Clinical profile and risk factors for mortality among COVID-19 inpatients at a tertiary care centre in Bengaluru, India

Cited by 10 publications

References 27 publications

Prevalence of co-morbidities and its association with mortality in Indian patients with COVID-19: A meta-analysis

Prevalence of co-morbidities and its association with mortality in Indian patients with COVID-19: A meta-analysis

Clinicoepidemiological profile of COVID-19 patients admitted at a teaching institute in a hilly area of India during the second wave—A retrospective observational study

Prevalence of comorbid tuberculosis amongst COVID‐19 patients: A rapid review and meta‐analysis

Contact Info

Product

Resources

About